- Home
- FT vs RPTX Comparison
FT vs RPTX Comparison
Compare FT & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- RPTX
- Stock Information
- Founded
- FT 1988
- RPTX 2016
- Country
- FT United States
- RPTX Canada
- Employees
- FT N/A
- RPTX N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- RPTX Health Care
- Exchange
- FT Nasdaq
- RPTX Nasdaq
- Market Cap
- FT 189.6M
- RPTX 152.4M
- IPO Year
- FT N/A
- RPTX 2020
- Fundamental
- Price
- FT $7.59
- RPTX $2.97
- Analyst Decision
- FT
- RPTX Strong Buy
- Analyst Count
- FT 0
- RPTX 1
- Target Price
- FT N/A
- RPTX $10.00
- AVG Volume (30 Days)
- FT 63.0K
- RPTX 113.0K
- Earning Date
- FT 01-01-0001
- RPTX 11-07-2024
- Dividend Yield
- FT 7.85%
- RPTX N/A
- EPS Growth
- FT N/A
- RPTX N/A
- EPS
- FT N/A
- RPTX N/A
- Revenue
- FT N/A
- RPTX $66,524,000.00
- Revenue This Year
- FT N/A
- RPTX $13.36
- Revenue Next Year
- FT N/A
- RPTX N/A
- P/E Ratio
- FT N/A
- RPTX N/A
- Revenue Growth
- FT N/A
- RPTX 18.19
- 52 Week Low
- FT $5.97
- RPTX $2.71
- 52 Week High
- FT $7.23
- RPTX $8.49
- Technical
- Relative Strength Index (RSI)
- FT 56.85
- RPTX 39.57
- Support Level
- FT $7.36
- RPTX $2.81
- Resistance Level
- FT $7.57
- RPTX $4.05
- Average True Range (ATR)
- FT 0.09
- RPTX 0.27
- MACD
- FT 0.01
- RPTX -0.08
- Stochastic Oscillator
- FT 63.79
- RPTX 16.92
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.